8-K filing — LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)
Filed: 2026-10-20 AccNo: 0001005286-26-000040 Size: 142 KB Item 8.01: Other Events
Stocks · News reference
William Blair Downgrades Lifecore Biomedical to Market Perform
William Blair analyst Max Smock downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lifecore Biomedical Q2 2026 Earnings Call Transcript
Lifecore Biomedical (NASDAQ:LFCR) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data
Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools Bankruptcy
Major M&A deals include Valley National buys Bluevine, Roland Foods buys Savor Brands, Bloomberg completes Canoe deal.
Wynnefield Capital Discloses About 14.3% Stake In Lifecore Biomedical, Agrees To Vote In Favor Of Its Pending Merger, Per 13D Filing